| |
|
|
| Saturday,
September 9 |
| |
| 10:00
am - 04:00 pm Live
Surgery |
| 05:00
pm - 07:00 pm Fluorescein
Angiography & Surgical Case Conference |
| 08:00
pm - 11:00 pm Welcome
Reception and Dinner |
|
|
|
Sunday,
September 10
|
| |
| 08:00 |
Opening
of continuing Film Projection |
| 08:00 |
Opening
Remarks Julia Haller, Didier Ducournau & Jean-Paul Amar
|
| |
| 08:05 |
Symposium
I: Anti-Angiogenesis (Part 1)
Presiding Officer: Susan B; Bressler Chair: Ursula Schmidt-Erfurth Moderator:
Tom S. Chang |
| |
| 08:05 |
Combined
efficacy of intravitreal ranibizumab in two Phase III studies of CNV
secondary to ARMD
Anat Loewenstein
|
| 08:12 |
Combined
Safety of Intravitreal Ranibizumab in Two Phase III Studies of CNV Secondary
to ARMD Paolo
Lanzetta |
| 08:19 |
Two-year
efficacy and safety results from the MARINA study
Ursula Schmidt-Erfurth |
| 08:26 |
Consistency
of effect of ranibizumab at 2 doses on contrast sensitivity in 3 Phase
III and IIIB studies of patients with CNV secondary to AMD
Jean-Francois Korobelnik |
| 08:33 |
Discussion
|
| 08:37 |
Intravitreal
Ranibizumab (LucentisTM) plus Verteporfin PDT for Neovascular ARMD: FOCUS
2-year Results
Andrew Antoszyk |
| 08:44 |
PIER:
Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety
in CNV Due to ARMD
Prema Abraham |
| 08:51 |
Pier:
Year 1 FA/OCT Results in a study of Ranibizumab (Lucentis™) for CNV Due
to ARMD William
F. Mieler |
| 08:58 |
An
OCT-Guided Variable-Dosing Regimen with Lucentis™ (Ranibizumab) in Neovascular
AMD: One Year Results from the PrONTO Study
Philip J. Rosenfeld |
| 09:05 |
Discussion
|
| 09:10 |
Introduction
of Featured Guest Lecture: Judah Folkman
Presiding Officers: Didier Ducournau, Julia Haller and Gene de Juan
|
| 09:15 |
Potential
Future Advances in Ophthalmology from Research in Tumor Angiogenesis
Judah Folkman, MD |
| 10:00 |
Discussion |
| 10:05 |
Poster
Session (AMD/ANTI-ANGIOGENESIS) |
| |
| 10:40 |
Symposium
II: Anti-Angiogenesis (Part 2) Presiding Officer: Lawrence
Singerman Chair: David Williams Moderators: Frank Koch |
| |
| 10:40 |
Open-label,
multicenter, Phase II Study Assessing the safety and efficacy of same-day
Verteporfin and liquid ranibizumab 0.5mg (PROTECT study)
Sebastian Wolf |
| 10:47 |
Ranibizumab
(Lucentis) Vision-Specific Quality of Life Trough 24 Months in Neovascular
ARMD Subjects in Marina: A Phase III Clinical Trial Tom
S. Chang |
| 10:54 |
Vision-Specific
Quality of Life at 12 Months in Predominantly Classic Neovascular ARMD
in Anchor: A Phase III Trial of Ranibizumab and Verteporfin PDT Neil
M. Bressler |
| 11:01 |
The
Value and Cost-Effectiveness of Interventions for Subfoveal Neovascular
ARMD Melissa
Brown |
| 11:08 |
Discussion |
| 11:12 |
Intravitreally
Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye
Tongalp Tezel |
| 11:16 |
Pharmacokinetics
of Intravitreal Bevacizumab (Avastin)
Sophie J. Bakri |
| 11:20 |
Vitreous
Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth
Factors in Two Human Subjects
Paul M. Beer |
| 11:24 |
Stability
of bevacizumab (Avastin) after withdrawal into a syringe and refrigeration
or freezing
Colin A. McCannel |
| 11:28 |
Discussion |
| 11:31 |
Intravitreal
Bevacizumab for the treatment of CNV secondary to Ocular Histoplasmosis
and Multifocal Choroiditis
Sundeep Dev |
| 11:36 |
Short-Term
Outcomes in over 500 Intravitreal Bevacizumab Treatments for Retinal or
CVD at the New York Eye & Ear Infirmary
Thomas O. Muldoon |
| 11:41 |
Intravitreal
Bevacizumab As Isolated First Line Therapy In Patients With New Untreated
CNV Membranes
Alay Banker |
| 11:46 |
Six-month
Follow up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections
for Neovascular ARMD Samira
Khan |
| 11:51 |
Discussion |
| 11:55 |
Primary
Intravitreal Bevacizumab (Avastin) for the Treatment of CNV secondary
to ARMD: Results of the Pan-American Collaborative Retina Study Group
Jans Fromow-Guerra |
| 12:00 |
Intravitreal
Bevacizumab (Avastin) for the Treatment of Neovascular ARMD
Alessandro Castellarin |
| 12:05 |
Intravitreal
Bevacizumab (Avastin™) for Primary Treatment of Neovascular ARMD David
F. Williams |
| 12:10 |
Intravitreal
Bevacizumab (Avastin) Treatment of CNV Secondary to ARMD
Richard F. Spaide |
| 12:15 |
Discussion
|
| 12:18 |
Time
to recurrence of ARMD-related CNV leakage after a single initial intravitreous
injection bevacizumab (Avastin®): Implications for a retreatment Edgar
L. Thomas |
| 12:23 |
A
FA/ICG analysis of the retinal/choroidal vasculature and CNV membrane
complex six months following intravitreal Avastin injections
Paul E. Tornambe |
| 12:28 |
Intravitreal
Bevacizumab Compared with PDT for Juxtafoveal CNV Membranes in ARMD
Derek Barker |
| 12:33 |
Combination
therapy for wet ARMD using verteporfin PDT and intravitreal bevacizumab
Jose Dalma-Weiszhausz |
| 12:38 |
Discussion
|
| 12:41 |
Combined
PDT with Verteporfin and Intravitreal Bevacizumab for CNV in ARMD
Gaurav K. Shah |
| 12:46 |
Combined
PDT with Verteporfin and Intravitreal Bevacizumab for Subfoveal CNV in
ARMD David
Misch |
| 12:51 |
Combination
Avastin and Reduced Fluence PDT for CNV David
Callanan |
| 12:56 |
Intravitreal
Bevacizumab (Avastin) enhanced Pegaptanib (Macugen) therapy for CNV in
ARMD: An Avastin Booster
Michael J. Tolentino |
| 01:01 |
Vitrectomy
in Triple Therapy for CNV
Frank H.J. Koch |
| 01:06 |
Discussion
|
| 01:10 |
Young
Physicians Section' Lunch |
| |
Crystal
Apple Lecture: Controversies in the Management and Prevention of Endophthalmitis
Harry W. Flynn, MD |
| |
| 02:40 |
Symposium
III: Anti-Angiogenesis (Part 3) Presiding Officer: Paul
E. Tornambe Chair: Anthony Adamis Moderator: Albert Augustin |
| |
| 02:40 |
C.L.E.A.R.
- IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal
VEGFTrap in Patients with Neovascular ARMD Quan
Dong Nguyen |
| 02:47 |
VEGF
small interfering (si) RNA, for Treatment of Wet ARMD
Lawrence J. Singerman |
| 02:54 |
The
Effects of Combined Inhibition of PDGF-B and VEGF-A Signaling in Murine
Models of Ocular Neovascularization
Anthony Adamis |
| 03:00 |
The
Role of a Selective VEGF Blockade in ARMD
Thomas R. Friberg |
| 03:06 |
Anecortave
Acetate Clinical Update
Peter K. Kaiser |
| 03:12 |
Discussion
|
| 03:16 |
Combined
IVT with PDT for the treatment of CNV in ARMD
Catherine Favard |
| 03:22 |
The
effect of Kenalog as adjunctive treatment to Visudyne in minimally classic
and occult neovascular ARMD: A prospective, randomized clinical trial
Tom Sheidow |
| 03:28 |
Six-month
Results of a Randomized, Double-Masked, Controlled Trial of IVT as an
Adjunct to PDT in Predominantly Classic Neovascular ARMD. The Canadian
RETINA Study
David Maberley |
| 03:34 |
Large
case series of different types of CNV after Combination Treatment (PDT
with intravitreal Triamcinolone)
Albert J. Augustin |
| 03:40 |
Discussion
|
| 03:45 |
AMD-panel
Moderator: Philip J. Rosenfeld |
| |
| Monday,
September 11 |
| |
| 08:00 |
Opening
of continuing Film Projection |
| |
08:00
|
Awards
& Special Presentations Presiding Officers: Julia Haller,
Gene de Juan, and George Williams |
| |
08:00
|
Introduction
of Pyron Award Winner
Brooks W. McCuen, II |
| 08:05 |
Pyron
Award Lecture: Evolving Concepts in Pharmacologic Vitreolysis
Brooks W. McCuen, II |
| 08:35 |
Introduction
of Founders Award Winner
Kirk H. Packo |
08:40
|
Founders
Award Lecture: Vitrectomy Technology - Where We've Been. Where We Are.
Where We Are Going. Kirk
H. Packo |
| 09:10 |
Pay
for Performance: A True Quality Initiative or a Means of Cost Control
William L. Rich, III |
| 09:20 |
American
Retina Foundation
Roy A. Levit |
| 09:25 |
Young
Phisicians Section's Crystal Apple Award Presentation |
| 09:27 |
PAT
Survey Award |
09:30
|
ASRS
Business Meeting |
10:00
|
Break/Exhibits/Poster
Session (IMAGING/SURGICAL DEVICES & INSTRUMENTATION/PHARMACOLOGY/SOCIOECONOMICS) |
| |
10:40
|
Symposium
IV: Imaging and AMD Presiding Officer: Giovanni Staurenghi
, Chair: Claude Boscher, Moderator: Gregg Kokame |
| |
| 10:40 |
Retinal
Measurements with 3D-OCT Alexander
C. Walsh |
10:45
|
SOCT
“Copernicus” a new diagnostic tool in retinology
Jerzy Nawrocki |
10:50
|
Active
CNV Without Subretinal or Intraretinal Fluid on OCT Imaging
G. Baker Hubbard |
10:55
|
Dualing
OCT Modalities: Contrasting Retinal Features Revealed by a Dual Mode High
Speed Ultrahigh Resolution Spectral and Temporal OCT/SLO Imager
Richard B. Rosen |
11:00
|
Spectral
Domain OCT Provides New Insight Into the Extent of Macular Pathology in
ARMD Cynthia
A. Toth |
11:05
|
Discussion
|
11:08
|
AMD,
hypertension and potential cardiovascular risks with intravitreal Avastin
injection Claude
Boscher |
11:13
|
Humanistic
Burden and Health Resource Utilization in Neovascular ARMD Patients from
Five Countries
Gisele Soubrane |
11:17
|
Comparison
of Comorbid Conditions Between Wet ARMD Patients and a Control Cohort
in the Medicare Population
Gergana Zlateva |
11:22
|
Myocardial
Infarction and Cerebrovascular Accident Rates in Patients with Neovascular
ARMD in a Healthcare Claims Database Emily
S. West |
| 11:27 |
Annual
Rates of Cardiovascular Events in Medicare Neovascular ARMD Patients
Tsontcho Ianchulev |
11:32
|
Discussion
|
11:36
|
Long
Term Results of the Age-Related Eye Disease Study
Emily Y. Chew |
11:41
|
Vitamin
Usage Patterns in the Prevention of Advanced ARMD in a Tertiary Care Population Susan B.
Bressler |
11:46
|
Discussion
|
11:51
|
Effect
of Initial Visual Acuity on Visual Loss in Untreated ARMD Eyes with Subfoveal
Neovascularization
Lucian Del Priore |
11:56
|
Incident
CNV Lesions in the Fellow Eyes of Participants with Unilateral Neovascular
ARMD during the Submacular Surgery
Trials Sharon D. Solomon |
| 12:01 |
Quantitative
OCT Sub-Analysis in Neovascular ARMD
SriniVas Sadda |
| 12:06 |
Treatment
of Retinal Angiomatous Proliferation Lesions Associated with Pigment Epithelial
Detachment with Focal Pulsed Laser Robert
P. Murphy |
| 12:11 |
Results
of a 1 Year Study of Feeder Vessel Therapy in ARMD
Giovanni Staurenghi |
| 12:15 |
Discussion
|
| 12:18 |
How
many days after onset is it too late to evacuate submacular hemorrhage
secondary to ARMD? Keye
L. Wong |
| 12:23 |
Pneumatic
displacement of submacular hemorrhage- a case series
Wilson Heriot |
| 12:28 |
Comparison
of Submacular Surgery and Natural History for the Treatment of Large Submacular
Hemorrhages from MD
John T. Thompson |
| 12:33 |
Recurrent
CNV after Macular Translocation Surgery With 360-degree Peripheral Retinectomy
Claxton A. Baer (Winner 2006 B&L Retina Fellows' Forum Research
Award) |
12:38
|
Subretinal
Surgery for Peripapillary Subretinal Neovascular Membranes
Gregg T. Kokame |
| 12:42 |
Discussion |
| 12:45 |
Prolonged
Choroidal Hypofluorescence following Verteporfin PDT Combined with Intravitreal
Triamcinolone Acetate Injection for Age-related CNVM Jeffrey
K. Luttrull |
| 12:50 |
Increased
Visual Acuity in Fellow Affected Eyes of Subjects Undergoing Therapy with
Intravenous EVIZON™ (Squalamine lactate) for Exudative ARMD
Michael Gast |
12:55
|
Two-year
Phase II/III Results (IMT002) of a Visual Prosthesis for Treatment of
Central Vision Loss due to End-Stage Macular Degeneration
Henry L. Hudson |
01:00
|
Discussion |
| |
02:10
|
Symposium
V: Surgical Devices and Instrumentation (Part 1) Presiding
Officer: Mike Trese, Chair: Tarek S. Hassan, Moderator: Claus Eckardt
|
| |
| 02:10 |
Evaluation
of the Artificial Silicon Retina™ Device for the Treatment of Vision Loss
from Retinitis Pigmentosa
John S. Pollack |
| 02:15 |
Chronic
retinal chip implant in blind patients with retinitis pigmentosa Gisbert
Richard |
| 02:20 |
Results
from a Chronically Implanted 16-Channel Epiretinal Prosthesis in Blind
Subjects Robert
J. Greenberg |
02:25
|
Discussion
|
| 02:28 |
Shedding
More Light on Endoillumination David
R. Chow |
02:33
|
Initial
Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment
of Retinal Diseases Julia
A. Haller |
| 02:38 |
Results
of Ophthalmic Surgical Training Using a High-fidelity Surgical Simulator
Coupled with a Curriculum Based on Task Breakdown and Analysis
Michael Grodin |
| 02:43 |
Cannulation
of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone
Acetonide and Bevacizumab Timothy
W. Olsen |
| 02:48 |
Enzymatic
Alteration of Vitreous Cavity Oxygen Levels
Michael T. Trese |
| 02:53 |
Discussion
|
| 02:56 |
20
Gauge Sutureless Transconjunctival Vitrectomy Daniel
Polya |
| 03:01 |
Transconjunctival
20-G Sutureless Vitrectomy
Mikael Sebag |
| 03:06 |
Discussion
|
| 03:09 |
25
Gauge Vitrectomy: Outcomes and Complications
Carl Regillo |
| 03:14 |
Complications
of 25-gauge Vitrectomy Surgery
Robert A. Mittra |
| 03:19 |
A
Head-to-Head Intraoperative Clinical Comparison of Flow Rates: Electric
vs. Pneumatic 25-gauge High-Speed Vitreous Cutters
Tarek S. Hassan |
| 03:24 |
Discussion
|
| 03:27 |
23-Gauge
Vitrectomy as an effective and safe alternative for sutureless vitreous
surgery Keith
A. Warren |
| 03:31 |
23-Gauge
Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications
Harinderjit Singh |
| 03:35 |
Further
experience with 23-gauge transconjunctival vitrectomy
Claus Eckardt |
| 03:40 |
23g
Sutureless Vitrectomy: When and Why? Zoran
Tomic |
03:44
|
A
new 23 Gauge Vitrectomy System
George A. Williams |
| 03:49 |
New
Devices for Vitreoretinal Surgery
Carl C. Awh |
| 03:54 |
Discussion |
| 03:57 |
Surgical
Devices and Instrumentation Panel Discussion
Moderator: Carl C. Awh |
04:15
|
EVRS
Business Meeting |
07:20
|
Coach
transportation to Palm Beach Casino |
| 07:30 |
Casablanca
Night at Palm Beach Casino |
| |
| Tuesday,
September 12 |
| |
| 08:00 |
Opening
of continuing Film Projection |
| |
| 08:00 |
Symposium
VI: Surgical Devices and Instrumentation (Part 2) Presiding
Officer: Suber Huang, Chair: Steve Charles, Moderator: Oswaldo Brasil,
Sr. |
| |
| 08:00 |
Comparison
Of Wound Leakage Between Straight And Tunnel Scleral Incisions After 25
Gauge Vitrectomy
Luiz Hagemann |
| 08:05 |
The
integrity of wound closure after 23 versus 25 gauge sutureless vitrectomy
Oswaldo Moura Brasil, Jr. |
| 08:10 |
Unfavorable
Surgical Events in 25 vs. 20 Gauge Vitreous Surgery Saad
A. Shaikh |
| 08:15 |
Comparison
of visual recovery time in patients undergoing 20g and 25 gauge vitreous
surgery Suber
S. Huang |
| 08:20 |
Discussion |
| 08:25 |
Vitreous
Dynamics: The New Solid Development Concept. Vitreous Flow Analysis in
20, 23 and 25 Gauge Cutters
Octaviano Magalhaes |
| 08:30 |
Fluid
dynamics among different 25-gauge systems: principles for use in vitreoretinal
surgery Michel
E. Farah |
| 08:35 |
Improved
understanding of TSV-25g Vitrectomy system: Qualitative High Speed Video
Analysis Of Vitreous Movement Around Aperture of Vitreous Cutters
Mark S. Humayun |
| 08:40 |
Interface
Vitrectomy Steve
T. Charles |
| 08:45 |
Passive
Removal of Silicone Oil with 25-Gauge Transconjunctival Sutureless Vitrectomy
Instruments
Ziya Kapran |
| 08:50 |
Discussion |
| |
| 08:55 |
Symposium
VII: Retinal Vascular Disease and Oncology Presiding Officer:
Suber Huang, Chair: Steve T. Charles, Moderator: Oswaldo Brasil, Sr.
|
| |
| 08:55 |
Reversal
of Ischemic CRVO: A Novel Technique of Multiple Retinal Vein Decompression
and Chorioretinal Venous Anastomosis
Calvin A. Grant |
| 09:00 |
Radial
optic neurotomy plus IVT with and without ILM peeling for CRVO
Jose Garcia-Arumi |
| 09:05 |
Safety
Profile of Various Steroids on Retinal Cells In Vitro
Baruch D. Kuppermann |
| 09:10 |
Discussion |
| 09:14 |
Pegaptanib
Sodium for the Treatment of ME Following CRVO
John Wells |
| 09:19 |
Short
Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab for
ME Secondary to CRVO
Jose A. Roca |
| 09:24 |
Intravitreal
Bevacizumab For Treatment Of ME In Central And BRVO Ajay
Dudani |
| 09:29 |
Ranibizumab
(Lucentis) in ischemic CRVO: intermediate OCT and visual results from
the RAVE trial Matthew
S. Benz |
| 09:34 |
Discussion |
| 09:38 |
Retinoblastoma
Tumor Vascular Heterogeneity: A Model for Angiogenic Vacular Maturation
and Implications for Vascular Targeting Therapy
Timothy G. Murray |
| 09:44 |
Standard
and High Resolution Echographic Features of Melanocytoma
Amy C. Schefler |
| 09:50 |
Discussion |
| 10:00 |
Poster
Session (DIABETIC RETINOPATHY/RETINAL VASCULAR DISEASE & ONCOLOGY/MACULAR
SURGERY) |
| |
| 10:40 |
Symposium
VIII: Diabetic Retinopathy (Part 1) Presiding Officer: J.
Fernando Arevalo, Chair: Athanasios Nikolakopoulus, Moderator: Robert
L. Avery |
| |
| 10:40 |
Clinical
Detection of DME Using the Automated Retinal Imaging System
Antonio P. Ciardella |
| 10:45 |
Factors
Influencing Utilization of a Telemedicine Diabetic Retinopathy Assessment
Program in the Primary Care Setting Ingrid
E. Zimmer-Galler |
| 10:50 |
Diurnal
Variation in Retinal Thickening Measured by OCT
Michel J. Shami |
| 10:55 |
Discussion
|
| 10:59 |
Subthreshold
Micropulse Diode Laser Photocoagulation in the treatment of diabetic clinically
significant ME Neelakshi
Bhagat |
| 11:04
|
VEGF
small interfering (si) RNA, Cand5, for Treatment of DME Jonathan
L. Prenner |
| 11:09
|
Three-Year
Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide
Intravitreal Implant to Treat DME
Dean Eliott |
| 11:14 |
The
I-vation Sustained Release Drug Delivery System and Intravitreal Implant Eugene de Juan, Jr. |
| 11:19 |
Discussion |
| 11:22 |
The
Effect of the Oral PKC ? Inhibitor Ruboxistaurin on Visual Loss and DME
Ronald P. Danis |
| 11:27 |
The
Effect of an Epiretinal Membrane on IVT Treatment for DME Parin
S. Gohel |
| 11:32 |
Predictive
factors for visual outcome after IVT acetonide injection for DME
Rishi Singh |
| 11:37 |
Discussion
|
| 11:40 |
Pegaptanib
Sodium in Diabetic Retinopathy: Improvements in DME, RNV, and Severity
of Diabetic Retinopathy
Victor Hugo Gonzalez |
| 11:45 |
OCT
Following Pegaptanib Therapy in Diabetics: a Bioanatomic Study of DME
David R. Guyer |
| 11:50 |
Intravitreal
injection versus systemic Bevacizumab(Avastin) Therapy for DME
Murat Oncel |
| 11:55 |
Discussion |
| 11:58 |
Interim
Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in
Diabetes Diana
V. Do |
| 12:03 |
Primary
Intravitreal Bevacizumab (Avastin) for the Treatment of DME: Results of
the Pan-American Collaborative Retina Study Group
J. Fernando Arevalo |
| 12:08 |
Intravitreal
Bevacizumab (Avastin) in the Treatment of PDR
Robert L. Avery |
| 12:15 |
Injection
of Intravitreal Avastin before Vitrectomy Surgery in the treatment of
Severe PDR Stanislao
Rizzo |
| 12:20 |
Discussion |
| 12:23 |
A
Simple Predictor of Vitrase® Efficacy for BCVA Improvement in Patients
with Diabetes and Severe Vitreous Hemorrhage Abdhish
R. Bhavsar |
| 12:29 |
Vitrase
for Vitreous Hemorrhage Revisited Michael
A. Singer |
| 12:35 |
Discussion
|
| 12:38 |
25
Gauge Vitrectomy for Advanced PDR: A Consecutive Case Series Including
Complex RD Firas
M. Rahhal |
| 12:44 |
Diabetic
traction detachment treated with bimanual 25g sutureless surgery (Is silicon
oil necessary?)
Athanasios Nikolakopoulos |
| 12:50 |
Reoperation
After Diabetic Vitrectomy: Rate, Indications, Visual Outcomes, and Complications
in an Urban Academic Medical Center Julie
Gasperini |
| 12:56 |
Posterior
Juxtascleral Injection of Triamcinolone Acetonide for Cases of Diabetic
ME Unresponsive or Unamenable to Laser Treatment Franco
M. Recchia |
| 01:02 |
Vitrectomy
for DME: study design and preliminary results of VIDE Study, an Italian
clinical trial
Barbara Parolini |
| 01:08 |
Discussion |
| |
| 02:15 |
Symposium
VIII: Diabetic Retinopathy (Part 2) |
| |
| 02:15 |
Panel
Discussion Moderator:
Harry W. Flynn Panelists: Tarek S. Hassan, Rodrigo Jorge, Frank HJ Koch,
Brooks W. McCuen, II, Robert P. Murphy, Georgiy Stolyarenko |
| |
| 02:45 |
Symposium
IX: Macular Surgery Presiding Officer: Claudio Azzolini
, Chair: Fabio Patelli , Moderator: Keye Wong |
| |
| 02:45 |
Posterior
RD and retinoschisis without a MH in highly myopic eyes: Clinical findings
and management Hassan
Mortada |
| 02:51 |
Myopic
Traction Maculopathy: A Slowly Progressive and Treatable Disease
Giacomo A. Panozzo |
| 02:57 |
Discussion
|
| 03:02 |
25
Gauge Macular Surgery: Results and Complications
Fabio Patelli |
| 03:08 |
Surgical
Treatment of Macular Pucker: Multicenter Clinical Trial Claudio
Azzolini |
| 03:14 |
Outcomes
of 25 gauge transconjonctival membrane peeling combined with sutureless
phaco/IOL surgery Jean-Paul
Berrod |
| 03:20 |
Discussion |
| 03:25 |
Combined
Phacoemulsification and Vitrectomy for MH Repair Ioannis
Theocharis |
| 03:31 |
Prospective
randomized clinical trial comparing face down position and semi seated
position after surgery for idiopathic full-thickness MH Alexandre
Guillaubey |
| 03:37 |
ILM
peeling prevents late reopening of closed MH
Thierry C. Verstraeten |
| 03:43 |
25
Gauge Transconjunctival Sutureless Vitrectomy for MH repair: how can we
resolve technique-related problems?
Federica Genovesi-Ebert |
| 03:49 |
Results
of Surgical Management of Senile MH by 25-Gauge Trans-Conjunctival Sutureless
Vitrectomy Compared to Standard Vitrectomy Systems
C. Christopher Brown |
| 03:55 |
Idiopathic
MH Following Pars Plana Vitrectomy For RD Francesco
Boscia |
| 04:01 |
Discussion |
| 06:30 |
Closing
Night Festivities |
| 06:30 |
Film
Festival Awards Ceremony / Gala
Dinner / Nightclub |
| |
| Wednesday,
September 13 |
| |
| 08:00 |
Opening
of continuing Film Projection |
| |
| 08:00 |
Symposium
X: Retinal Detachment Presiding Officer: Giampaolo Gini,
Chair: Klaus Lucke, Moderator: Masoud Soheilian |
| |
| 08:00 |
The
Value and Cost-Effectiveness of Vitreoretinal Interventions
Gary C. Brown |
| 08:06 |
Rhegmatogenous
RD in myopic eyes after LASIK. Characteristics, surgical management and
functional outcomes
Anna Boixadera |
| 08:12 |
Use
of 25-Gauge Pars Plana Vitrectomy Surgery for Primary Repair of Rhegmatogenous
RD Amitabh
Bharadwaj |
| 08:18 |
Discussion |
| 08:20 |
Visual
and Anatomic Outcomes of Pneumatic Retinopexy
Daniel B. Roth |
| 08:26 |
Results
of Pneumatic Retinopexy in Phakic Eyes - A Prospective Comparison of the
Clinical Trial Group Inclusion Criteria and Extended Criteria
Stephen M. Conti |
| 08:32 |
Discussion
|
| 08:35 |
Optic
Pit RD - Attempt at a Unifying Theory Klaus
Lucke |
| 08:41 |
Multiples
Macular RD After successful Buckle Surgery: Infrared, Autofluorescence,
oct and Microperimetric features
Francesco Faraldi |
| 08:47 |
Discussion |
| 08:50 |
Incidence
of RD after macular surgery: a retrospective study of 634 cases
Catherine Creuzot |
| 08:56 |
Cataract
Surgery and Vitrectomy for PVR: comparaisons Between Internal Tamponades
and Lens Removal Techniques
Marcio B. Nehemy |
| 09:02 |
Triamcinolone
Acetonide in Silicone-filled Eyes as Adjunctive Treatment for PVR: A Randomized
Clinical Trial
Hamid Ahmadieh |
| 09:08 |
Effect
of Intraoperative 5-Fluorouracil and Low Molecular Weight Heparin on the
Outcome in High-Risk PVR Guruprasad
S. Ayachit |
| 09:14 |
Primary
Vitrectomy in the Treatment of RD in Highly Myopic Eyes with Axial Length
Over 30mm Gregoire
Minoyan |
| 09:20 |
Discussion |
| |
| 09:23 |
Symposium
XI: Trauma Presiding Officer: Giampaolo Gini, Chair: Klaus
Lucke , Moderator: Masoud Soheilian |
| |
| 09:23 |
Microbial
Isolates and Sensitivities in Posterior-Segment Intraocular Foreign Body
Injuries: A 10-year Review Samuel
B. Barone |
| 09:30 |
Prophylaxis
of Acute Post-Traumatic Bacterial Endophthalmitis with and without Intraocular
Antibiotic injection
Masoud Soheilian |
| 09:37 |
Intraocular
Foreign Body Removal at Walter Reed Army Medical Center During Operations
Iraqi and Enduring Freedom
Marcus Colyer |
| 09:44 |
Management
of traumatic RD associated with open globe injuries Giampaolo
Gini |
| 09:51 |
Discussion |
| 10:00 |
Poster
Session (PEDIATRIC AND INFLAMMATORY DISEASE/HEREDITARY RETINAL DISEASE
& GENETICS/RETINAL DETACHMENT/TRAUMA) |
| |
| 10:40 |
Symposium
XII: Pediatrics and Inflammatory Disease Presiding Officer:
Harry Flynn, Chair: Silvia Bopp, Moderator: Dan Martin |
| |
| 10:40 |
Screening
for retinopathy in the pediatric sickle cell patient population Harmeet
Gill |
| 10:46 |
PFV:
Clinical Spectrum and Therapeutic Approach
Silvia Bopp |
| 10:52 |
Discussion |
| 10:57 |
Telemedicine
Screening for Retinopathy of Prematurity: The Stanford Experience (SUNDROP)
Steven R. Sanislo |
| 11:03 |
Safety
and efficacy of intravitreal bevacizumab for retinopathy of prematurity
Hugo Quiroz-Mercado |
| 11:09 |
Anti-VEGF
Therapy for Pediatric Retinopathies: Which Case is the Right Case?
Kimberly A. Drenser |
| 11:15 |
Discussion |
| 11:20 |
Endophthalmitis
in the Newborn
Kristen Hartley |
| 11:26 |
A
2006 Update on the Risks Associated with Intravitreous Injection and Guidelines
for Safe Administration Emmett
T. Cunningham |
| 11:32 |
Acute-onset
Endophthalmitis Following Clear Corneal Cataract Surgery (1996-2005):
Clinical Features, Microbiology and Visual Outcomes Geeta
Lalwani |
| 11:38 |
Early
Onset Endophthalmitis Caused by Aspergillus Species Following Cataract
Surgery Harry
W. Flynn, Jr. |
| 11:44 |
Discussion |
| 11:47 |
25-Gauge
Vitrectomy Management of Severe Post-Cataract Surgery Endophthalmitis Flavio A.
Rezende |
| 11:53 |
Complete
and Early Vitrectomy for Eyes with Postoperative Endophthalmitis
Ferenc Kuhn |
| 11:59 |
In-office
And Bedside Sutureless Vitrectomy for The Diagnosis Of Uveitis
Robert G. Josephberg |
| 12:05 |
Three-Year
Results of a Multi-Center Clinical Trial of Fluocinolone Acetonide Intravitreal
Implants to Treat Posterior Uveitis
Daniel F. Martin |
| 12:11 |
Discussion
|
| |
| 12:15 |
Symposium
XIII: Future Directions Presiding Officer: Harry W. Flynn,
Chair: Silvia Bopp, Moderator: Daniel F. Martin |
| |
| 12:15 |
Sub-retinal
injection of Bevacizumab (Avastin) in treating neovascular ARMD, 25 gauge
approach Ehab
El-Rayes |
| 12:20 |
Rationale
for Genistein in the Prevention and Treatment of Diabetic Retinopathy
Michael J. Cooney |
| 12:25 |
Application
of Proteomic Analysis to Characterize the Molecular Pathways of the Vitreous
and Retina in Health and Disease
Bert M. Glaser |
| 12:30 |
Ultra-Wide
Angle Fluorescein Angiographic Evaluation of the Retinal Periphery in
the Management of Retinal Vascular Diseases
Steven D. Schwartz |
| 12:35 |
New
Pharmacologic Treatments for Retinal Disease: A Venture Capital Perspective
Gilbert H. Kliman |
| 12:42 |
Discussion
|
| 12:47 |
Closing
remarks |
